These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 21584491)

  • 1. Effects of affinity on binding of HER2-targeting Affibody molecules: model experiments in breast cancer spheroids.
    Qvarnström OF; Simonsson M; Carlsson J; Tran TA
    Int J Oncol; 2011 Aug; 39(2):353-9. PubMed ID: 21584491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Affibody-displaying bionanocapsules for specific drug delivery to HER2-expressing cancer cells.
    Shishido T; Mieda H; Hwang SY; Nishimura Y; Tanaka T; Ogino C; Fukuda H; Kondo A
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5726-31. PubMed ID: 20801029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of an optimized scaffold for affibody molecules.
    Feldwisch J; Tolmachev V; Lendel C; Herne N; Sjöberg A; Larsson B; Rosik D; Lindqvist E; Fant G; Höidén-Guthenberg I; Galli J; Jonasson P; Abrahmsén L
    J Mol Biol; 2010 Apr; 398(2):232-47. PubMed ID: 20226194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors.
    Orlova A; Tolmachev V; Pehrson R; Lindborg M; Tran T; Sandström M; Nilsson FY; Wennborg A; Abrahmsén L; Feldwisch J
    Cancer Res; 2007 Mar; 67(5):2178-86. PubMed ID: 17332348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule.
    Nishimura Y; Mimura W; Mohamed Suffian IF; Amino T; Ishii J; Ogino C; Kondo A
    J Biochem; 2013 Mar; 153(3):251-6. PubMed ID: 23235317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule.
    Vernet E; Konrad A; Lundberg E; Nygren PA; Gräslund T
    J Immunol Methods; 2008 Sep; 338(1-2):1-6. PubMed ID: 18671978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.
    Baum RP; Prasad V; Müller D; Schuchardt C; Orlova A; Wennborg A; Tolmachev V; Feldwisch J
    J Nucl Med; 2010 Jun; 51(6):892-7. PubMed ID: 20484419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples.
    Lundberg E; Höidén-Guthenberg I; Larsson B; Uhlén M; Gräslund T
    J Immunol Methods; 2007 Jan; 319(1-2):53-63. PubMed ID: 17196217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
    Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
    Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody.
    Mume E; Orlova A; Larsson B; Nilsson AS; Nilsson FY; Sjöberg S; Tolmachev V
    Bioconjug Chem; 2005; 16(6):1547-55. PubMed ID: 16287254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
    Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
    Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of necrosis-linked p53 aggregation in acquired apoptotic resistance to 5-FU in MCF-7 multicellular tumour spheroids.
    Lee SY; Jeong EK; Jeon HM; Kim CH; Kang HS
    Oncol Rep; 2010 Jul; 24(1):73-9. PubMed ID: 20514446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers.
    Wållberg H; Orlova A
    Cancer Biother Radiopharm; 2008 Aug; 23(4):435-42. PubMed ID: 18771347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simplified characterization through site-specific protease-mediated release of affinity proteins selected by staphylococcal display.
    Kronqvist N; Löfblom J; Severa D; Ståhl S; Wernérus H
    FEMS Microbiol Lett; 2008 Jan; 278(1):128-36. PubMed ID: 18034830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand.
    Tran T; Orlova A; Sivaev I; Sandström M; Tolmachev V
    Int J Mol Med; 2007 Mar; 19(3):485-93. PubMed ID: 17273798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor.
    Friedman M; Nordberg E; Höidén-Guthenberg I; Brismar H; Adams GP; Nilsson FY; Carlsson J; Ståhl S
    Protein Eng Des Sel; 2007 Apr; 20(4):189-99. PubMed ID: 17452435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention.
    Graff CP; Wittrup KD
    Cancer Res; 2003 Mar; 63(6):1288-96. PubMed ID: 12649189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of CCL2-CCR2A/2B signaling for monocyte migration into spheroids of breast cancer-derived fibroblasts.
    Ksiazkiewicz M; Gottfried E; Kreutz M; Mack M; Hofstaedter F; Kunz-Schughart LA
    Immunobiology; 2010; 215(9-10):737-47. PubMed ID: 20605053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.